Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Berko

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2026
Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk NeuroblastomaNurit Gal-Mark, Assaf Grunwald, Valid Gahramanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group StudyEsther R Berko, Arlene Naranjo, Alexander A Daniels, et al.
Bulletin of Experimental Biology and Medicine|November 29, 2019
Effects of Bariatric Surgeries on the Size of Myocardial Infarction and Ghrelin Level in Rats with Experimental Decompensated Type 2 Diabetes MellitusO V Kornyushin, D L Sonin, Ya G Toropova, et al.
Cancer Research Communications|November 16, 2022
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastomaKateryna Krytska, Colleen E Casey, Jennifer Pogoriler, et al.
BMC Medicine|August 5, 2015
The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal?Perianayagam Arokiasamy, Uttamacharya Uttamacharya, Kshipra Jain, et al.
Journal of Medical Genetics|July 9, 2016
De novo missense variants in HECW2 are associated with neurodevelopmental delay and hypotoniaEsther R Berko, Megan T Cho, Christine Eng, et al.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Infectious Diseases of Poverty|August 16, 2023
Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectinKenneth Bentum Otabil, Blessing Ankrah, Emmanuel John Bart-Plange, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization ConsortiumInge M W Verberk, Mariam Gouda, Daniel Antwi-Berko, et al.
Nature Communications|May 5, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastomaEsther R Berko, Gabriela M Witek, Smita Matkar, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2026
Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk NeuroblastomaNurit Gal-Mark, Assaf Grunwald, Valid Gahramanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group StudyEsther R Berko, Arlene Naranjo, Alexander A Daniels, et al.
Bulletin of Experimental Biology and Medicine|November 29, 2019
Effects of Bariatric Surgeries on the Size of Myocardial Infarction and Ghrelin Level in Rats with Experimental Decompensated Type 2 Diabetes MellitusO V Kornyushin, D L Sonin, Ya G Toropova, et al.
Cancer Research Communications|November 16, 2022
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastomaKateryna Krytska, Colleen E Casey, Jennifer Pogoriler, et al.
BMC Medicine|August 5, 2015
The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal?Perianayagam Arokiasamy, Uttamacharya Uttamacharya, Kshipra Jain, et al.
Journal of Medical Genetics|July 9, 2016
De novo missense variants in HECW2 are associated with neurodevelopmental delay and hypotoniaEsther R Berko, Megan T Cho, Christine Eng, et al.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Infectious Diseases of Poverty|August 16, 2023
Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectinKenneth Bentum Otabil, Blessing Ankrah, Emmanuel John Bart-Plange, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization ConsortiumInge M W Verberk, Mariam Gouda, Daniel Antwi-Berko, et al.
Nature Communications|May 5, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastomaEsther R Berko, Gabriela M Witek, Smita Matkar, et al.
Pageof 24